| abstract |
The present invention relates to pharmaceutically active compounds of formula (I) which inhibit the vitronectin receptor, wherein R 1 is Het or Ar; and R 2 is a group and a pharmaceutically acceptable salt thereof. The compounds of the present invention are useful in the treatment of inflammation, cancer and cardiovascular disorders, such as atherosclerosis and restenosis, and diseases in which bone resorption is involved, such as osteoporosis. The invention also relates to pharmaceutical compositions containing the compounds. SHE |